GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Gross-Profit-to-Asset %

Heidelberg Pharma AG (XTER:HPHA) Gross-Profit-to-Asset % : 7.50% (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Heidelberg Pharma AG's annualized Gross Profit for the quarter that ended in Feb. 2024 was €4.95 Mil. Heidelberg Pharma AG's average Total Assets over the quarter that ended in Feb. 2024 was €66.01 Mil. Therefore, Heidelberg Pharma AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2024 was 7.50%.


Heidelberg Pharma AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Heidelberg Pharma AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Gross-Profit-to-Asset % Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.18 13.56 -14.33 22.62 7.73

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.67 3.90 11.13 16.93 7.50

Competitive Comparison of Heidelberg Pharma AG's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Heidelberg Pharma AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Gross-Profit-to-Asset % falls into.



Heidelberg Pharma AG Gross-Profit-to-Asset % Calculation

Heidelberg Pharma AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Nov. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Nov. 2023 )/( (Total Assets (A: Nov. 2022 )+Total Assets (A: Nov. 2023 ))/ count )
=6.606/( (100.582+70.353)/ 2 )
=6.606/85.4675
=7.73 %

Heidelberg Pharma AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=4.948/( (70.353+61.666)/ 2 )
=4.948/66.0095
=7.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Feb. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Heidelberg Pharma AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines